Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRETON vs METROGEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Seasonal allergic conjunctivitis,Perennial allergic conjunctivitis,Other allergic ocular conditions
Topical treatment of inflammatory papules and pustules of rosacea,Treatment of bacterial vaginosis (off-label),Treatment of acne vulgaris (off-label)
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Not extensively metabolized; primarily excreted unchanged in urine.
Hepatic via glucuronidation and oxidation; metabolites excreted renally.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
75-85% bound to albumin and alpha-1-acid glycoprotein
Less than 20%; albumin.
0.5-1.0 L/kg; indicates moderate tissue distribution
0.25-0.85 L/kg; extensive tissue distribution including CSF.
Oral: 50-70% (first-pass metabolism); Intramuscular: 80-100%
Topical: minimal systemic absorption (2-4%); oral: 80-100%; intravenous: 100%.
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: administer every 12-18 hours or consider dose reduction by 50%.
No dose adjustment required for topical or intravaginal use; systemic absorption is minimal.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
No dose adjustment required; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
0.5-1 mg/kg intramuscularly or intravenously every 6-8 hours; maximum 25 mg per dose for children <40 kg.
Topical 1% gel: apply twice daily for children ≥12 years; safety and efficacy for rosacea in children <12 not established.
Start at lower end of dosing range (e.g., 0.5-1 mg/kg) with extended intervals (every 8-12 hours) due to decreased renal function and increased sensitivity.
No specific dose adjustment; use same dosing as adults; monitor for local adverse effects due to thinner skin.
None
No FDA black box warning.
Do not inject; for ophthalmic use only.,May cause transient burning or stinging.,Use with caution in patients with narrow-angle glaucoma.
Avoid unnecessary prolonged use; may cause peripheral neuropathy with chronic use; discontinue if neurological symptoms occur; photosensitivity reactions; avoid sun exposure.
Hypersensitivity to any component of the formulation
Hypersensitivity to metronidazole or any component of the formulation; concurrent disulfiram use; history of alcoholic beverage consumption during therapy.
Avoid excessive alcohol intake (increases risk of lactic acidosis). No specific food restrictions, but consistent carbohydrate intake is recommended to prevent hypoglycemia. Grapefruit may increase metformin levels (use caution).
No significant food interactions specific to topical metronidazole; however, systemic metronidazole has alcohol interaction (disulfiram-like reaction), so patients should avoid alcohol while using topical formulation? Although topical absorption is minimal, caution is advised. No specific dietary restrictions.
Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Second and third trimesters: Potential for intrauterine growth restriction, adrenal suppression in neonate. Avoid use unless benefit outweighs risk.
Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neurodevelopmental risks unclear.
Prednisolone and chlorpheniramine (components of METRETON) are excreted into breast milk. M/P ratio for prednisolone is approximately 0.5-0.7. Low risk at maternal doses <20 mg/day; higher doses may cause infant adrenal suppression or growth delay. Consider alternative antihistamine with lower excretion.
Excreted in breast milk; M/P ratio ~1.0; American Academy of Pediatrics considers compatible; delay breastfeeding 12-24h after IV dose.
No specific dose adjustment required; use lowest effective dose for shortest duration. Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may reduce efficacy of standard doses; monitor clinical response and consider dose titration. Avoid high-dose or prolonged therapy.
No dose adjustment required for topical METROGEL; systemic absorption negligible.
METRETON is a fixed-dose combination of metformin and sitagliptin. Use with caution in patients with renal impairment (check e GFR before initiation; contraindicated if e GFR <30 m L/min/1.73 m²). Monitor for lactic acidosis, especially in hypoxic states or hepatic impairment. Discontinue temporarily before iodinated contrast imaging and for surgery. Assess for pancreatitis (discontinue if suspected). Do not use in type 1 diabetes or diabetic ketoacidosis. Dose adjustment of sitagliptin needed if e GFR 30-45 m L/min/1.73 m² (50 mg daily).
Metro Gel (metronidazole topical gel) is first-line for rosacea papules/pustules; avoid use in ocular rosacea as it can worsen symptoms. It is not effective for erythematotelangiectatic rosacea. For bacterial vaginosis, oral or intravaginal metronidazole is preferred; Metro Gel is not FDA-approved for vaginosis. In acne, it is less effective than topical antibiotics like clindamycin. Warn patients about rare metallic taste if gel is applied near lips.
Take with meals to reduce gastrointestinal side effects.,Do not drink excessive alcohol while taking this medication.,Monitor for symptoms of lactic acidosis (unusual tiredness, muscle pain, trouble breathing, stomach pain) and pancreatitis (severe stomach pain, nausea, vomiting).,Inform your doctor if you become pregnant or plan to breastfeed.,Report any signs of allergic reaction (rash, hives, swelling of face/lips/throat) immediately.,Maintain adequate fluid intake, especially during illness or in hot weather.,Do not skip meals or drastically reduce carbohydrate intake without consulting your provider.
Apply a thin layer to affected areas once or twice daily as directed; avoid contact with eyes, mouth, and mucous membranes.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,Avoid sun exposure; use sunscreen and protective clothing as metronidazole may increase sensitivity to UV light.,Report any signs of allergic reaction (rash, itching, swelling) or worsening skin redness.,If accidental ingestion occurs, seek medical attention immediately; metronidazole can cause systemic side effects.,Do not use during pregnancy (especially first trimester) or while breastfeeding without consulting your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRETON vs METROGEL, answered by our medical review team.
METRETON is a Antibiotic (Nitroimidazole) that works by Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.. METROGEL is a Antibiotic (Nitroimidazole) that works by Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRETON and METROGEL depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRETON is: 1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.. The standard adult dose of METROGEL is: Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRETON and METROGEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRETON is classified as Category C. Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Seco. METROGEL is classified as Category C. Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.